Cipher Genetics, Inc. – Trademark Portfolio
Entity Type: 03
Cipher Genetics, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 5 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 1 trademark is registered and 2 are pending. Notable registered marks include GENES 1ST. The owner is based in Bellevue, WA.
3120 139th Ave. SE Suite 500
Bellevue, WA 98005
Showing of trademarks Trademarks
Trademark Classifications
Cipher Genetics, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Cipher Genetics, Inc. have?
Cipher Genetics, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 pending, 2 abandoned.
What trademark classes does Cipher Genetics, Inc. file in?
Cipher Genetics, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Cipher Genetics, Inc.'s most well-known trademarks?
Cipher Genetics, Inc.'s registered trademark portfolio includes well-known marks such as GENES 1ST. These are among 1 currently registered trademark in the portfolio.
What is Cipher Genetics, Inc.'s trademark registration success rate?
Cipher Genetics, Inc. has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 2 applications are pending review.